Preventive effect of *Catharanthus roseus* (Linn.) against high-fructose diet-induced insulin resistance and oxidative stress in male Wistar rats

Karuna Rasineni, Saralakumari Desireddy

Department of Biochemistry, Sri Krishnadevaraya University, Anantapur, India; *Corresponding Author: skumari1@yahoo.co.in

Received 6 June 2011; revised 15 July 2011; accepted 26 July 2011.

**ABSTRACT**

High intake of dietary fructose has been shown to exert a number of adverse metabolic effects in humans and experimental animals. The aim of the present study was to investigate whether *Catharanthus roseus* (L.) G. Don (Apocynaceae) leaf powder alleviates high-fructose diet-induced insulin resistance and oxidative stress in rats. Adult male Wistar rats of body weight around 200 g were divided into four groups, two of which were fed with standard pellet diet and the other two with high fructose (66%) diet. *C. roseus* leaf powder suspension in water (100 mg/kg body weight/day) was administered orally to each group of the standard pellet diet fed rats and the high fructose diet fed rats for 60 days. Fructose-fed rats (F-group) showed hyperglycemia, hyperinsulinemia, insulin resistance and hyperlipidemia (P < 0.05). *C. roseus* treatment in fructose-fed rats (F+CR-group) prevented the rise in glucose levels by 32.2%, insulin by 46.4%, and impaired insulin sensitivity by 63.6%. *C. roseus* treatment completely prevented the fructose-induced plasma lipid alterations. Regarding liver antioxidant status, oxidative stress was observed in fructose-fed rats (F-group), while *C. roseus* treatment in F+CR-group prevented the fructose-induced oxidative stress. Our data indicate the preventive role of *C. roseus* against fructose-induced insulin resistance and oxidative stress; hence this plant can be used as an adjuvant for the prevention and/or management of insulin resistance and disorders related to it.

**Keywords:** *Catharanthus roseus*; Insulin Resistance; Fructose Diet; HOMA; Oxidative Stress

**1. INTRODUCTION**

The last 25 years have witnessed a marked increase in total per capita fructose intake as a sweetener in the food industry, primarily in the form of sucrose (a disaccharide consisting of 50% fructose) and high-fructose corn syrup (HFCS; 55% - 90% fructose content) [1]. Processed-food manufacturers often prefer HFCS to sucrose because it is inexpensive, sweeter and mixes well in many foods. The increase in HFCS consumption far exceeds the increases in intake of any other food or food group. The disturbing fact is fructose consumption (excluding that which occurs naturally in fruits and vegetables) increased from less than 0.5 g/day in 1970 to more than 40 g/day in 1997 (more than an 80-fold increase) [2].

High intake of dietary fructose exerts a number of adverse health effects in humans and experimental animals including obesity, hypertriglyceridemia, hyperinsulinemia, glucose intolerance hyperuricemia, insulin resistance, hypertension, accelerated aging, non-alcoholic fatty liver disease, etc. [3-5]. This cluster of disorders is similar to those observed in human multimetabolic syndrome or syndrome X or insulin resistance syndrome, which is observed in prediabetic patients that progresses to type 2 diabetes mellitus and cardiovascular diseases. The fructose-fed rats are used as animal models of insulin resistance (IR) that is considered to parallel multimetabolic syndrome observed in humans [6]. Insulin sensitizers and antioxidants are found to be effective in preventing not all but at least a majority of the abnormalities induced by fructose [7,8]. Current treatment with thiazolidinediones and particularly metformin does not adequately address the issue of IR [9]. Hence, there is a need to search for new agents with better efficacy and minimal side effects. Actually, there is an enormous increase in the use of herbal and other alternative medicines for this target.
Catharanthus roseus (L.) G. Don (Apocynaceae) is known with various names (Madagascar periwinkle; Vinca rosea; Lochnera rosea). Catharanthus roseus is one of the few medicinal plants which have found mention in the folk medicinal literature. *C. roseus* alkaloids, vincristine and vinblastine, are widely used as chemotherapeutic agents against Leukemia and Hodgkin’s disease worldwide [10]. The fresh juice from the flowers of *C. roseus* made into a tea has been used by Ayurvedic physician in India for external use to treat dermatitis, eczema and acne [11]. The leaves of this plant has indeed been used to treat diabetes and often taken without adverse effects or toxicity. The antihyperglycemic activity of *C. roseus* leaf powder in STZ-induced diabetic rats was observed in our laboratory [12]. Fresh leaf juice of *C. roseus* has been reported to reduce blood glucose in normal and alloxan diabetic rabbits [13]. Significant antihyperglycemic activity of leaf alcoholic extract [14,15] and dichloromethane-methanol extract of leaves and twinges [16] have been reported in laboratory animals. The extracts of *C. roseus* have been reported to have human peroxisome proliferator receptor activating activity [17]. The leaf juice of *C. roseus* has been reported to reduce serum total cholesterol and triglyceride in rats [18]. However very little information is available on the role of *C. roseus* in the improvement of IR and antioxidant property. Hence, the present study has been undertaken to explore possible beneficial effects of *C. roseus* leaf powder in the prevention of fructose induced IR and oxidative stress in rats. 

2. MATERIALS AND METHODS

2.1. Plant Material

Catharanthus roseus was (white variety) taxonomically authenticated by the Department of Botany, Sri Krishnadevaraya University, Anantapur and the voucher specimen was kept in the herbarium (No. 2235) of our University. Fresh leaves of *C. roseus* (white variety) were collected during September, from the University campus and leaves were shade dried and then ground to fine powder. The powder was stored at 0°C - 4°C and dissolved in water just before administered to animals.

2.2. Rat Feed

The fructose diet and pellet diet were procured from National Centre for Animal Science, National Institute of Nutrition (Hyderabad, India). Fructose diet contains 66% fructose, 15% protein, 8% fat, 4% cellulose, 3.5% of each mineral and vitamin mix. Pellet diet had same composition except that fructose was replaced with starch.

2.3. Animal Model and Experimental Design

Male Albino Wistar rats (140 g - 160 g) used for the present study were procured from Sri Venkateswara Enterprises (Bangalore, India). The current work was carried out after approval by our institutional animal ethical committee (Regd. no. 470/01/a/CPCSEA). Before dietary manipulation, the animals were acclimatized for 7 days in our animal house. They were housed two per cage in an air-conditioned room (22°C ± 2°C) with 12 h light/dark cycle and had free access to standard pellet diet and water.

2.4. Experimental Design

All the animals were 6 weeks of age, weighing around 180 g at the time of dietary manipulation. Animals were randomly assigned into four groups of eight each as given below:

Group-C: control rats, fed with standard pellet diet,
Group-F: fructose fed rats, fed with fructose diet,
Group-F+CR: *C. roseus* treated fructose rats, fed with fructose diet and treated with *C. roseus* leaf powder,
Group-C+CR: *C. roseus* treated control rats, fed with standard pellet diet and treated with *C. roseus* leaf powder.

Group-F+CR and C+CR animals received *C. roseus* leaf powder suspension (100 mg/kg body weight) in 2 mL distilled water daily for 60 days through oral intubation, whereas 2 mL of distilled water was administered to C and F-group rats. The dose of *C. roseus* leaf powder used in the current study is based on our previous experiments on dose-dependent antihyperglycemic effect in STZ-induced diabetic rats [12]. During the experimental period blood was collected from 12 h fasted rats by means of capillary tubes through orbital sinus. The body weight, fasting plasma glucose and insulin were measured on initial, 15, 30, 45 and 60th day of experiment. Plasma lipids were measured on 60th day of experiment. At the end of experimental period animals were fasted over night and sacrificed by cervical decapitation. The body was cut open and liver was dissected out into ice cold saline and then thoroughly rinsed.

2.5. Biochemical Measurements

Plasma glucose was estimated by glucose oxidase-peroxidase (GOD-POD) method by using the Span diagnostic kit (Span diagnostic Ltd., Surath, India). Plasma total cholesterol (TC), triglycerides (TG) and HDL-cholesterol (HDL-C) were estimated by enzymatic colorimetric end point methods using Span diagnostic reagent kit. LDL-cholesterol (LDL-C) and VLDL-cholesterol (VLDL-C) were obtained by calculations using the formula provided in cholesterol diagnostic kit book.
let. Atherogenic index was calculated as TC/HDL-C. Plasma insulin was estimated by using radioimmunoassay kit (RIA K-1) from Bhabha Atomic Research Centre (Mumbai, India) according to the method of Yalow & Berson [19]. Homeostasis Model Assessment (HOMA), used as an index to measure the degree of IR, was calculated by the formula: Insulin (µU/ml) × Glucose (mmol/L)/22.5 [20].

The concentration of lipid peroxidation intermediates, liver thiobarbituric acid reactive substances (TBARS) was measured by following the method of Utley et al., [21] using 10% liver homogenate in 0.15 M KCl and expressed as nmol of Malondialdehyde (MDA) formed/min/mg protein. The extent of protein carbonyl groups [22] and reduced glutathione (GSH) levels [23] in liver were determined. Protein content in the liver homogenate was measured by the method of Lowry et al. [24].

2.6. Enzyme Assays

Ten percent liver homogenate was prepared in ice-cold 0.15 M KCl, centrifuged at 12,000 rpm for 45 min in Sigma Laboratory centrifuge 3K18 model, rotor No. 12150. The clear supematant thus obtained was used for the assay of superoxide dismutase (SOD; E.C.1.15.1.1) [25], catalase (CAT; E.C.1.11.1.6) [26], glutathione peroxidase (GPx; E.C.1.15.1.9) [27], glutathione-S-transferase (GST; E.C.2.5.1.14) [28], and glutathione reductase (GR; E.C.1.8.1.7) [29].

2.7. Statistical Analysis

All results were expressed as means ± SEM for the number, n = 8 of animals in the group as indicated in the figures and table. To determine the statistical significance of clinical and laboratory findings Duncan Multiple Range test (DMRT) (P < 0.05) was used.

3. RESULTS

3.1. General Characteristics

No visible side effects and variation in animal behavior (respiratory distress, abnormal locomotion and catalepsy) were observed in experimental animals.

3.2. Body Weight

The body weights of four groups of animals during the experimental period are represented in Figure 1. From initial day of experiment to the end of experimental period, the gain in body weight in C, C+CR, F and F+CR-groups were 94, 95, 116.5 and 98.6 g respectively. No significant variation was observed regarding gain in body weight of C+CR and F+CR-groups when compared with C-group. By the end of experimental period, F-group gained 24% more body weight compared with C-group.

3.3. Fasting Blood Glucose

Data on plasma glucose content of the four experimental groups are represented in Figure 2. Control and C+CR and F+CR-groups remained persistently euglycemic throughout the experimental period. At the end of experimental period, plasma glucose level of F-group was significantly higher (52%) than those of C-group.

3.4. Fasting Plasma Insulin and IR (HOMA)

The fasting plasma insulin levels of four groups of the animals during experimental period were represented in Figure 3. Control-group showed no significant variation in the insulin levels during the experimental period. Control rats treated with C. roseus (C+CR-group) showed a gradual decrease in the insulin levels during experimental period with statistically lower insulin levels at 45 and 60 days when compared with C-rats. Group-F exhibited a gradual increase in plasma insulin during experimental period showing a significantly higher concentration of insulin at 15, 30, 45 and 60 days with 10.7%, 48.6%, 77% and 140% respectively when compared with C-group. The insulin levels of F+CR-group were 47.7 ± 1.4, 50.5 ± 1.6 and 57.6 ± 1.7 at 30, 45 and 60 days respectively with 66.8%, 75.7% and 79.7% recovery from fructose induced hyperinsulinemia. The insulin levels of F+CR-group at the end of experimental period were significantly lower (46.4%) than F-group but still significantly higher (28.4%) than C-group.
Figure 2. Mean plasma glucose of rats during experimental period. C: control rats; C+CR: control diet fed rats treated with C. roseus leaf powder at a dose of 100 mg/kg b.wt; F: fructose fed rats; F+CR: fructose fed rats treated with C. roseus leaf powder at a dose of 100 mg/kg b.wt. Values are mean ± S.E (n = 8). * Significant as compared to group-C (P < 0.05).

Figure 3. Mean plasma insulin of rats during experimental period. C: control rats; C+CR: control diet fed rats treated with C. roseus leaf powder at a dose of 100 mg/kg b.wt; F: fructose fed rats; F+CR: fructose fed rats treated with C. roseus leaf powder at a dose of 100 mg/kg b.wt. Values are mean ± S.E (n = 8). * Significant as compared to group-C (P < 0.05).

Figure 4. Mean HOMA values (fig 4) of rats during experimental period. (HOMA: Homeostasis model of assessment for insulin resistance was calculated as fasting plasma insulin (μU/ml) × fasting plasma glucose (mmol/l)/22.5). C: control rats; C+CR: control diet fed rats treated with C. roseus leaf powder; F: fructose fed rats; F+CR: fructose fed rats treated with C. roseus. Values are mean ± S.E (n = 8). * Significant as compared to group-C (P < 0.05).

3.5. Plasma Lipid Profile

At the end of experimental period a significant increase in plasma TC (62%), TG (105%), LDL-C (112.7%) and VLDL-C (104.5%) and a significant decrease (12%) in HDL-C in F-group compared to C-group resulted in a significant increase (80%) in atherogenic index. The triglyceride levels of group-F+CR showed no significant variation when compared with group-C. A significant decrease in plasma TC (9.8%), TG (7.2%), LDL-C (38.8%), VLDL-C (7.5%) and a significant increase (15%) in HDL-C concentration in C+CR-group compared to C-group lead to a significant decrease in atherogenic index (23.2%). (Table 1).

3.6. Hepatic Oxidative Stress Markers and Antioxidants

Table 2 summarizes the hepatic oxidative stress markers and antioxidants. Group-F showed a significantly higher levels of TBARS (33.2%) and protein carbonyl groups (26%) and low levels of hepatic GSH (23%) as compared to group-C rats. C. roseus treatment for 60 days prevented the increased tissue TBARS and protein carbonyl groups and decreased GSH levels in F+CR-group. Group-C+CR showed 8.6% increase in GSH levels when compared to group-C rats. The activities of enzymatic antioxidants GR, GPx, GST, SOD and CAT were significantly lower (9.31%, 14.4%, 14.2%, 19%, and 19%, respectively) in group-F rats than in group-C.
Table 1. The Effect of *C. roseus* on plasma lipid profile in control and fructose fed rats.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>C</th>
<th>C+CR</th>
<th>F</th>
<th>F+CR</th>
</tr>
</thead>
<tbody>
<tr>
<td>TC (mg/dL)</td>
<td>72.3 ±1.07</td>
<td>65.2 ±1.50*</td>
<td>117.2 ±1.83*</td>
<td>76.3 ±1.33*</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>76.3 ±1.93</td>
<td>70.8 ±0.97*</td>
<td>156.5 ±3.03*</td>
<td>80.5 ±2.92</td>
</tr>
<tr>
<td>HDL-C (mg/dL)</td>
<td>29.4 ±0.45</td>
<td>33.8 ±0.31*</td>
<td>25.9 ±0.65*</td>
<td>28.9 ±0.54</td>
</tr>
<tr>
<td>LDL-C (mg/dL)</td>
<td>28.2 ±1.03</td>
<td>17.1 ±1.35*</td>
<td>59.9 ±2.25*</td>
<td>31.2 ±1.49</td>
</tr>
<tr>
<td>VLDL-C (mg/dL)</td>
<td>15.3 ±0.49</td>
<td>14.2 ±0.19*</td>
<td>31.3 ±0.60*</td>
<td>16.5 ±0.78</td>
</tr>
<tr>
<td>Atherogenic index</td>
<td>2.5 ±0.10</td>
<td>1.9 ±0.08*</td>
<td>4.5 ±0.40*</td>
<td>2.5 ±0.07</td>
</tr>
</tbody>
</table>

C: control rats; C+CR: control diet fed rats treated with *C. roseus* leaf powder; F: fructose fed rats; F+CR: fructose fed rats treated with *C. roseus* leaf powder. Values are given as mean ± S.E (n = 8). * Significant as compared to group-C (P < 0.05).

Table 2. Effect of *C. roseus* on hepatic oxidative stress markers and antioxidants.

<table>
<thead>
<tr>
<th>Parameters</th>
<th>C</th>
<th>C+CR</th>
<th>F</th>
<th>F+CR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lipid peroxidation (nmol of MDA formed/ min/mg protein)</td>
<td>20.33 ± 1.12</td>
<td>18.81 ± 0.61</td>
<td>27.08 ± 0.63*</td>
<td>1.11 ± 0.63</td>
</tr>
<tr>
<td>Protein oxidation (µmol of protein carbonyls/mg protein)</td>
<td>7.51 ± 0.49</td>
<td>7.11 ± 0.54</td>
<td>9.47 ± 0.56*</td>
<td>7.72 ± 0.47</td>
</tr>
<tr>
<td>GSH (µg/mg protein)</td>
<td>5.55 ± 0.20</td>
<td>6.03 ± 0.20*</td>
<td>4.28 ± 0.25*</td>
<td>5.58 ± 0.18</td>
</tr>
<tr>
<td>Glutathione reductase (µmol of NADPH oxidized/min/mg protein)</td>
<td>34.04 ± 0.61</td>
<td>35.38 ± 0.77</td>
<td>30.87 ± 0.86*</td>
<td>34.33 ± 0.42</td>
</tr>
<tr>
<td>Glutathione peroxidase (µg of GSH consumed/ min mg protein)</td>
<td>9.45 ± 0.15</td>
<td>9.76 ± 0.13</td>
<td>8.09 ± 0.14*</td>
<td>10.00 ± 0.51</td>
</tr>
<tr>
<td>Glutathione-S-transferase (mmol of CDNB-GSH conjugate formed/min/mg protein)</td>
<td>0.232 ± 0.005</td>
<td>0.220 ± 0.004</td>
<td>0.199 ± 0.005*</td>
<td>0.228 ± 0.006</td>
</tr>
<tr>
<td>Superoxide dismutase (U/mg protein)</td>
<td>45.30 ± 1.31</td>
<td>46.85 ± 1.69</td>
<td>36.66 ± 1.45*</td>
<td>46.72 ± 2.18</td>
</tr>
<tr>
<td>Catalase (µmol of H₂O₂ consumed/min/mg protein)</td>
<td>99.84 ± 4.40</td>
<td>101.55 ± 4.20</td>
<td>80.81 ± 2.92*</td>
<td>100.95 ± 3.77</td>
</tr>
</tbody>
</table>

SOD-1U = Amount of enzyme which gave 50% inhibition of pyrogallol autooxidation/min. Catalase: µmol of H₂O₂ consumed/min/mg protein. C: control rats; C+CR: control diet fed rats treated with *C. roseus* leaf powder; F: fructose fed rats; F+CR: fructose fed rats treated with *C. roseus* leaf powder. Values are given as mean ± S.E (n = 8). * Significant as compared to group-C (P < 0.05).

rats. In group-F+CR, the activities were significantly higher (11.2%, 23.6%, 14.5%, 27.4% and 25%, respectively) as compared to group-F.

4. DISCUSSION

Insulin resistance is a wide spread feature of atherogenic diseases, predisposes the affected individuals to various diseases including hypertension, dyslipidemia, cardiovascular problems and type 2 diabetes mellitus [30]. Information is available in experimental animals on the metabolic and endocrine effects of dietary fructose suggesting that increased consumption of fructose may be detrimental in terms of body weight and adiposity and the metabolic indices associated with the insulin resistance syndrome [4] and it was also observed in our laboratory [5]. In the present study, high fructose feeding resulted in significant increase in the body weight, fasting hyperglycemia, hypertriglyceridemia, hyperinsulinemia, glucose intolerance and impaired antioxidant potential leading to the development of insulin resistance.

In experimental animals fructose feeding resulted in a significant increase in the body weight from 15 days till the end of experimental period. Insulin is involved in the regulation of body adiposity via its action on the central nervous system (CNS) to inhibit food intake and increase energy expenditure. Thus, reduced insulin delivery into the CNS or disruption of the insulin-signaling pathway in CNS may result in the weight gain and development of obesity [31]. It is noteworthy that *C. roseus* treatment prevented weight gain in fructose fed rats despite increased energy intake. The reason for this behavior may be the interference of *C. roseus* on the fructose-induced lipid synthesis.

In the present study fructose fed animals showed a significantly enhanced plasma glucose, insulin and IR as reflected by increased HOMA value from 15 days on words till the end of the experimental period. The plasma glucose values of *C. roseus* treated fructose fed rats (F+CR-group) were in control levels and plasma insulin and HOMA values were significantly higher than the control values, but these values were significantly low when compared with F-group. Thus *C. roseus* has shown protection against hyperglycemia and a partial prevention of hyperinsulinemia and IR in fructose fed rats. The significantly decreased plasma insulin and HOMA levels at 60 days of C+CR-group with normo-
glycemia represent the enhanced insulin sensitivity of these animals compared to C-group. Indeed, insulin sensitizers have shown their ability to improve insulin sensitivity in many ways, such as effect on muscle insulin sensitivity, stimulation of insulin-sensitive fat cells, and regulation of leptin expression [32]. The question, whether the mechanism by which \textit{C. roseus} improves insulin sensitivity by its direct effects on target tissues or indirectly through endogenous substances, requires further study in future.

The dyslipidemia observed in fructose fed rats was reflected by significantly enhanced plasma TG, TC, LDL-C and VLDL-C with significantly decreased HDL-C. Thus fructose fed rats showed higher atherogenic index, which is the risk factors for coronary heart disease. High levels of plasma triacylglycerols are a well-established consequence of dietary fructose intake. Numerous mechanisms have been suggested to explain this phenomenon. The fructose is more lipogenic than glucose and high concentration of fructose can serve as a relatively unregulated source of acetyl-CoA. It continues to enter the glycolytic pathway distal to phosphofructokinase, and hepatic triacyl-glycerol production is facilitated. Increased delivery of triglycerides to the muscle interferes with the utilization of glucose, through the principles of Randle cycle [33], impairing insulin action leading to hyperglycemia and hyperinsulinemia. As insulin resistance and reduced insulin binding have been reported in hypertriglycerolemic persons [34], this may be one mechanism by which fructose diets promote insulin resistance. \textit{C. roseus} treatment completely prevented fructose-induced hyperglycemia and partially prevented hyperinsulinemia in group-F clearly indicates the development of oxidative stress in fructose fed rats and it could cause impaired insulin function in insulin resistance condition. Previous studies strongly suggest that oxidative stress occurs in rats fed a high fructose diet [35].

Peroxidative deterioration of lipids is evident with the lower activity of glutathione reductase enzyme.

5. CONCLUSION

Our experimental data clearly indicate that \textit{C. roseus} leaf powder is capable of attenuating the development of IR, compensatory hyperinsulinemia and dyslipidemia induced by fructose diet. These favorable effects might be due to different types of active principles acting individually or synergistically each with a single or a diverse range of biological activities. These results may lend further support to mount up evidence that \textit{C. roseus} leaf powder is capable of attenuating the development of IR, compensatory hyperinsulinemia and dyslipidemia induced by fructose diet. These favorable effects might be due to different types of active principles acting individually or synergistically each with a single or a diverse range of biological activities. These results may lend further support to mount up evidence that \textit{C. roseus} contains compounds which, if taken in sufficient quantities, could conceivably be beneficial in attenuation and prevention of insulin resistance. Further studies are required to establish the mechanism(s) underlying this effect of \textit{C. roseus}. In conclusion, \textit{C. roseus} leaf powder would seem useful as an adjuvant for the prevention and/or management of pre-diabetic state of insulin resistance and for subjects who need to increase insulin sensitivity.

6. ACKNOWLEDGEMENTS

We appreciate National Centre for Laboratory Animal Sciences, Hyderabad for the kind supply of fructose feed for experimental ani-
Copyright © 2011 SciRes.
Openly accessible at http://www.scirp.org/journal/JDM/


